Telocinobufagin (Telobufotoxin)
(Synonyms: 远华蟾蜍精,Telobufotoxin; Telocinobufogenin) 目录号 : GC33530
一键复制产品信息
Telocinobufagin (Telobufotoxin)是一种从蟾蜍皮肤分泌物中分离的强心甾类化合物。Telocinobufagin通过抑制STAT3、JAK2/STAT3、LARP1-mTOR、PI3K/Akt/Snail和PLK1等多条信号通路来发挥生物学功能。
Cas No.:472-26-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Telocinobufagin (Telobufotoxin) is a cardenolide compound isolated from toad skin secretions. Telocinobufagin exerts its biological functions by inhibiting multiple signaling pathways, including STAT3, JAK2/STAT3, LARP1-mTOR, PI3K/Akt/Snail, and PLK1[1-2]. Telocinobufagin can be used in research related to various cancers, renal fibrosis, and analgesia[3-4].
In vitro, 4T1 breast cancer cells were treated with Telocinobufagin (0.05-1.5μg/ml) for 24-48 hours. By inhibiting the PI3K/Akt/ERK/Snail signaling pathway, Telocinobufagin significantly inhibited the migration and invasion capabilities of the cells[5]. CAL-62 undifferentiated thyroid carcinoma cells were treated with Telocinobufagin (0-2μg/mL) for 24 hours. By downregulating the expression of LARP1 and the activity of the mTOR signaling pathway, Telocinobufagin significantly inhibited the proliferation, migration, invasion, and adhesion capabilities of the cells[6].
In vivo, wild-type (WT) and heterozygous NKAα-1+/- mice were subjected to continuous intraperitoneal infusion of Telocinobufagin (0.1mg/kg/day) via osmotic minipumps for 4 weeks. Telocinobufagin infusion led to a significant increase in proteinuria and elevated plasma cystatin C levels, and induced mild to moderate periglomerular and peritubular fibrosis in the renal cortex of WT mice, whereas renal function impairment and fibrosis were significantly attenuated in NKAα-1+/- mice[7]. In acute pain model Swiss Webster mice, a single administration of Telocinobufagin (0.1-4mg/kg; intraperitoneal injection; or 0.1-40mg/kg; oral) was performed. Telocinobufagin demonstrated dose-dependent potent antinociceptive activity, inhibiting over 90% of nociceptive responses at the highest tested dose, with a potency approximately 4 times that of morphine[8].
References:
[1] Cao Y, Song Y, An N, et al. The effects of telocinobufagin isolated from Chan Su on the activation and cytokine secretion of immunocytes in vitro. Fundam Clin Pharmacol. 2009 Aug;23(4):457-64.
[2] Ma X, Xu W, Jin X, et al. Telocinobufagin inhibits osteosarcoma growth and metastasis by inhibiting the JAK2/STAT3 signaling pathway. Eur J Pharmacol. 2023 Mar 5;942:175529.
[3] Zhang DM, Liu JS, Tang MK, et al. Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis. Eur J Pharmacol. 2012 Oct 5;692(1-3):19-28.
[4] Khalaf FK, Tassavvor I, Mohamed A, et al. Epithelial and Endothelial Adhesion of Immune Cells Is Enhanced by Cardiotonic Steroid Signaling Through Na+/K+-ATPase-α-1. J Am Heart Assoc. 2020 Feb 4;9(3):e013933.
[5] Gao Y, Shi L, Cao Z, et al. Telocinobufagin inhibits the epithelial-mesenchymal transition of breast cancer cells through the phosphoinositide 3-kinase/protein kinase B/extracellular signal-regulated kinase/Snail signaling pathway. Oncol Lett. 2018 May;15(5):7837-7845.
[6] Qiang LZ, Fang SZ. Telocinobufagin suppresses malignant metastasis of undifferentiated thyroid carcinoma via modulation of the LARP1-mTOR pathway. Kaohsiung J Med Sci. 2025 Mar;41(3):e12934.
[7] Kennedy DJ, Khalaf FK, Sheehy B, et al. Telocinobufagin, a Novel Cardiotonic Steroid, Promotes Renal Fibrosis via Na⁺/K⁺-ATPase Profibrotic Signaling Pathways. Int J Mol Sci. 2018 Aug 29;19(9):2566.
[8] Feitosa GIMC, Carvalho IF, Coelho EBS, et al. Potent nonopioid antinociceptive activity of telocinobufagin in models of acute pain in mice. Pain Rep. 2019 Oct 8;4(6):e791.
Telocinobufagin (Telobufotoxin)是一种从蟾蜍皮肤分泌物中分离的强心甾类化合物。Telocinobufagin通过抑制STAT3、JAK2/STAT3、LARP1-mTOR、PI3K/Akt/Snail和PLK1等多条信号通路来发挥生物学功能[1-2]。Telocinobufagin可用多种癌症、肾脏纤维化和镇痛等相关研究[3-4]。
在体外，Telocinobufagin（0.05-1.5μg/ml）处理4T1乳腺癌细胞24-48小时。Telocinobufagin通过对PI3K/Akt/ERK/Snail信号通路的抑制，显著抑制了细胞的迁移和侵袭能力[5]。Telocinobufagin（0-2μg/mL）处理CAL-62未分化甲状腺癌细胞24小时，Telocinobufagin通过下调LARP1的表达和mTOR信号通路的活性，显著抑制了细胞的增殖、迁移、侵袭和粘附能力[6]。
在体内，Telocinobufagin（0.1mg/kg/day）通过渗透性微型泵对野生型（WT）及NKAα-1+/-基因型小鼠进行为期4周的腹腔持续输注。Telocinobufagin可导致野生型小鼠出现显著的蛋白尿增加和血浆胱抑素C水平升高，并引发轻至中度的肾脏皮质肾小球及肾小管周围纤维化，而NKAα-1+/-小鼠的肾功能损伤和纤维化则被显著减弱[7]。Telocinobufagin（0.1-4mg/kg；腹腔注射；或0.1-40mg/kg；口服）单次给药处理急性疼痛模型Swiss Webster小鼠。Telocinobufagin显示出剂量依赖性的强效抗伤害感受活性，在最高测试剂量下能抑制90%以上的伤害性反应，效力约为吗啡的4倍[8]。
| Cell experiment [1]: | |
Cell lines | 4T1 cells (mouse breast cancer cell line) |
Preparation Method | 4T1 cells were maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) at 37°C, 5% CO₂. 4T1 cells were treated with Telocinobufagin (0.05-1.5μg/ml) for 24-48 hours. |
Reaction Conditions | 0.05-1.5μg/ml; 24-48h. |
Applications | Telocinobufagin significantly inhibited the migration and invasion of 4T1 breast cancer cells. Telocinobufagin also triggered the collapse of F-actin filament cytoskeleton. Through the phosphoinositide 3-kinase/protein kinase B/extracellular signal-regulated kinase/Snail (PI3K/Akt/ERK/Snail) signaling pathway, Telocinobufagin downregulated mesenchymal markers (vimentin, fibronectin) and upregulated the epithelial marker E-cadherin. |
| Animal experiment [2]: | |
Animal models | Wild-type (WT) 129 SvJ/Black Swiss mice and heterozygous NKAα-1+/- mice. |
Preparation Method | Mice were infused with either Telocinobufagin (0.1mg/kg/day) or vehicle for 4 weeks via intraperitoneal osmotic minipumps. Renal function, histology, and gene expression were assessed at the end of the infusion period. |
Dosage form | 0.1mg/kg/day; continuous infusion via i.p. osmotic minipump; 4 weeks. |
Applications | Continuous Telocinobufagin infusion resulted in increased proteinuria and elevated plasma cystatin C in WT mice, indicating renal dysfunction, and induced mild to moderate periglomerular and peritubular fibrosis in the renal cortex. These pro-fibrotic and dysfunctional effects were significantly attenuated in NKAα-1+/- mice. Both WT and NKAα-1+/- mice exhibited a similar significant increase in systolic blood pressure following Telocinobufagin infusion. |
References: | |
| Cas No. | 472-26-4 | SDF | |
| 别名 | 远华蟾蜍精,Telobufotoxin; Telocinobufogenin | ||
| Canonical SMILES | O[C@@]([C@@]1(CC2)C)(CC[C@@H]1C(C=C3)=COC3=O)[C@@](CC[C@@]45O)([H])[C@@]2([H])[C@]4(CC[C@H](O)C5)C | ||
| 分子式 | C24H34O5 | 分子量 | 402.52 |
| 溶解度 | DMSO : 50 mg/mL (124.22 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4843 mL | 12.4217 mL | 24.8435 mL |
| 5 mM | 496.9 μL | 2.4843 mL | 4.9687 mL |
| 10 mM | 248.4 μL | 1.2422 mL | 2.4843 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet